<DOC>
	<DOC>NCT01206101</DOC>
	<brief_summary>This trial is conducted in Europe and North America. The aim of this trial is to investigate if liraglutide treatment can increase the proportion of insulin-independent subjects one year after islet cell transplantation who required only one (single-donor) islet cell transplant.</brief_summary>
	<brief_title>Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes mellitus for at least 5 years Candidate for islet cell transplantation based upon local accepted practice and guidelines Reduced awareness of hypoglycaemia Treatment with any antidiabetic medication other than insulin including insulin pump within 4 weeks of trial start Any previous organ transplantation A history of acute idiopathic or chronic pancreatitis Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>